Twist Bioscience (TWST) Equity Ratio (2018 - 2026)

Twist Bioscience has disclosed Equity Ratio across 9 years of filings, most recently posting 0.67 for Q1 2026.

• In Q1 2026, Equity Ratio fell 8.92% year-over-year to 0.67; the TTM figure through Mar 2026 stood at 0.67 (down 8.92% YoY), while the FY2025 annual figure was 0.74, down 4.24% from the prior year.
• Equity Ratio slipped to 0.67 in Q1 2026, from 0.71 in the prior quarter.
• Over the last five years, Equity Ratio for TWST reached as high as 0.85 in Q1 2022 and fell as low as 0.67 in Q1 2026.
• The 5-year median for Equity Ratio is 0.8 (2024), against an average of 0.78.
• Annual changes were most pronounced in 2022 — Equity Ratio rose 2.97% — and 2026, when it slipped 8.92%.
• A 5-year view of Equity Ratio shows it stood at 0.82 in 2022, then retreated by 1.83% to 0.81 in 2023, then retreated by 6.95% to 0.75 in 2024, then slipped by 4.59% to 0.71 in 2025, then decreased by 5.85% to 0.67 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.67, 0.71, and 0.74 for Q1 2026, Q4 2025, and Q3 2025 respectively.